ProKidney is going public in a SPAC merger that infuses the biotech with $825 million for Phase 3 tests and manufacturing of its autologous cell therapy for chronic kidney disease. More than slowing the decline in organ function, ProKidney says its cell therapy offers the potential to reverse injury caused by the condition.
Palihapitiya s SPAC Merges with ProKidney themiddlemarket.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themiddlemarket.com Daily Mail and Mail on Sunday newspapers.
Revolutionary Chronic Kidney Disease Therapeutics Company ProKidney to Become Publicly Traded via Business Combination with Social Capital Suvretta Holdings Corp. III - read this article along with other careers information, tips and advice on BioSpace
A 36,000-gallon ocean and atmosphere simulator at UC San Diego's Scripps Institute of Oceanography will allow researchers to study interactions between wind, waves and microbial life with unprecedented accuracy.